Burning Rock Dx

Welcome to Burning Rock's U.S. Lab in Irvine, CA!🔬 Our lab is home to cutting-edge cancer genotyping technologies, specializing in both tissue and liquid biopsies. Certified under CLIA and accredited by CAP, our lab integrates advanced assay biochemistry, bioinformatics, and a patented laboratory information management system to drive precision medicine forward.💯 #BurningRockDx #PrecisionMedicine #NGS #PrecisionOncology #laboratory #biotech

OncoScreen® Plus is a CE-marked 518-gene panel for comprehensive mutation profiling of solid tumors. The kit detects key genetic alterations such as SNV, InDel, CNV, Fusion, MSI, and TMB, enabling personalized treatment strategies for immunotherapy and targeted therapy. This all-in-one genomic solution provides critical insights for both immunotherapy and targeted therapy, helping drive personalized cancer care with precision. Learn more:https://lnkd.in/gZ6PKTZR #BurningRockDx #PrecisionMedicine #NGS #PrecisionOncology #SolidTumor #Biomarkers #cancer

Burning Rock Dx is Heading to JPM 2025! We are thrilled to announce that our company will be participating in the highly anticipated J.P. Morgan Healthcare Conference 2025, taking place from January 13th to 16th in San Francisco. Our team is eager to engage in insightful discussions and explore potential collaborations at this premier event. Representing our department will be our Department Head, xinru mao along with our talented Translational Scientist, Chun (Michael) Chen and three of our outstanding Business Development colleagues, Shawn A., Alex Brand, and Liliang Jin In addition, our Department Head, Xinru Mao, will also be attending the BIO Partnering@JPM week conference. If you would like to schedule a meeting with us during this time, please visit the following link: https://lnkd.in/gXmz4RFF. We look forward to meeting fellow industry professionals and sharing ideas at these conferences. See you in San Francisco! #JPM2025 #HealthcareConference #BIOPartnering

🎆 Happy New Year! Wishing you a prosperous 2025! 🎆 🔬 As we look ahead to 2025, we are more committed than ever to advancing the frontiers of genomics, transforming cancer care, and making a meaningful difference in the lives of patients worldwide. We’re excited about the opportunities and breakthroughs the new year will bring. #BurningRockDx #PrecisionMedicine #NGS #happynewyear #happyholidays #cancercare #healthcare

🌟 Burning Rock Dx at J.P. Morgan Healthcare Conference 2025! 🌟 We’re thrilled to announce our participation in the upcoming J.P. Morgan Healthcare Conference, taking place from January 13-16, 2025, in San Francisco. Our attending team includes: 🔹 xinru mao Head of Pharma Biomarker & CDx Service; Head of International IVD Business 🔹 Chun (Michael) Chen Translational Medicine Scientist 🔹 Shawn A. and Alex Brand Director of Business Development We’re excited to discuss the latest advancements in NGS-based diagnostics, biomarker-driven therapy development, and to explore opportunities for collaboration with healthcare innovators and industry leaders. 💬 Interested in connecting with us? Schedule a meeting here: https://lnkd.in/gXmz4RFF Let’s innovate and shape the future of precision oncology together! 🔬✨ #BurningRockDx #JPM2025 #PrecisionOncology #HealthcareInnovation

🎅🏼 The festive season is here, and so is the joy! 🎅🏼 At Burning Rock, we're celebrating the magic of Christmas with warmth, laughter, and a lot of festive cheer! 🎄✨ 🍰 Indulging in sweet, delicious cakes and juicy chicken wings 🧋 Crafting our own special Christmas milk teas with all the toppings – who doesn’t love a little DIY fun? 🎉 Here’s to cozy moments and shared laughs as we wrap up the year with gratitude and joy. Wishing you all a Merry Christmas and a Happy New Year! 💝🎁 #BurningRockDx #MerryChristmas #Happyholidays #christmasparty #LoveMyTeam

Meet with our team, Shawn A., Alex Brand, Chun (Michael) Chen, and xinru mao at JPM Heathcare week December 11 - 16 in San Francisco to discuss NGS-based biomarker and CDx solutions with Burning Rock Dx

Last week, we concluded an insightful discussion on the development and regulatory journey of China’s first NGS-based companion diagnostic for lung cancer, co-developed by Burning Rock and Dizal. This CDx, approved by NMPA for EGFR exon 20 insertion mutations, marks a significant step in precision oncology. The session covered key topics on the development of companion diagnostics and targeted therapies, focusing on global opportunities and challenges. From regulatory strategies to clinical applications, we gained fresh insights into the evolving landscape of cancer care. Let's watch the experts share their valuable insights and experiences! #BurningRockDx #CompanionDiagnostic #NGS #NextGenDx #LungCancer #Cancer #TargetedTherapy #CDx #precisionmedicine #PrecisionOncology

🌟 Here are some highlight insights from Burning Rock, which showcased OncoScreen® Focus CDx(LungCure CDx) at three major industry events in China. At these conferences, we conducted in-depth discussions and analyses on key topics, including the EGFR ex20ins CDx and biomarker solutions for lung cancer. These platforms provided an excellent opportunity to engage with industry experts, exchange ideas, and share the latest insights in precision oncology. #BurningRockDx #NGS #PrecisionMedicine #Oncology #TargetSelection #Genomics #CompanionDiagnostic #LungCancer #Cancer #CDx 

Thank you Burning Rock and SABCS, our team thanks everyone for taking time to visit with us last week. We look forward to working together!